Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Ocugen Stock: Bull vs. Bear


When it comes to contentious stocks, Ocugen (NASDAQ: OCGN) is likely one of the market's leaders. The company is trying to commercialize its coronavirus vaccine candidate and it also boasts long-term growth potential stemming from its group of gene therapies in development for ocular disorders. It's easy to see why there's so much interest in its worthiness as an investment.

With a market cap of only $1.6 billion, it could have a massive amount of room to run. Let's take a look at one argument in favor of buying Ocugen stock and one argument against it to get a better sense of whether it'd be a good pick for your portfolio. 

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments